RVMD Stock Analysis: Revolution Medicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 44.556m USD | 12M Return: 439.2% | US76155X1000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 351M
Qual. Beats: -5
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 6.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Revolution Medicines (NASDAQ: RVMD) is a US-based, clinical-stage precision oncology company developing targeted therapies for cancers driven by RAS mutations. As a clinical-stage biotechnology, it has no approved products or commercial revenue from product sales, with its valuation tied to the progression of its R&D pipeline. The company was incorporated in 2014, completed its IPO in February 2020, and is headquartered in Redwood City, California.
The pipeline is built around two mechanisms: RAS(ON) inhibitors designed to bind active RAS protein variants, and RAS companion inhibitors that suppress cooperating pathways sustaining RAS-addicted tumors. Lead asset daraxonrasib (RMC-6236) is a pan-RAS(ON) inhibitor currently in a Phase 3 registrational trial in combination with zoldonrasib G12D (RMC-9805) in first-line pancreatic ductal adenocarcinoma (PDAC). Elironrasib G12C (RMC-6291) is in early clinical development for solid tumors. Earlier-stage candidates include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), each engineered against a specific RAS mutation.
- Daraxonrasib Phase 3 pancreatic cancer data readout approaches
- Cash burn accelerates ahead of multiple registrational trial milestones
- Competition intensifies from approved KRAS inhibitors Lumakras and Krazati
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA -13.87 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 > 3% & CFO -1.58b > Net Income -1.77b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (210.9m) vs 12m ago 12.09% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 10.77%; Δ -10.77% > 0%) |
| Interest Coverage Ratio: -27.42 > 6 (EBIT TTM -1.63b / Interest Expense TTM 59.3m) |
| A: 0.85 (Total Current Assets 4.03b - Total Current Liabilities 354.1m) / Total Assets 4.32b |
| B: -0.92 (Retained Earnings -3.97b / Total Assets 4.32b) |
| C: -0.48 (EBIT TTM -1.63b / Avg Total Assets 3.38b) |
| D: 1.52 (Book Value of Equity 2.61b / Total Liabilities 1.72b) |
| Altman-Z'' = 0.94 = BB |
As of September 05, 2026, the stock is trading at USD 210.02 with a total of 884,362 shares traded. Over the past week, the price has changed by +1.03%, over one month by +8.56%, over three months by +34.90% and over the past year by +439.20%.
Current recommended Stop Loss: 188.40 (which is 10.3% or 2.6 ATR below the current price).
Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 235.8 | 12.3% |
P/S = 9035.0954
P/B = 18.1923
Revenue TTM = 0.0 USD
EBIT TTM = -1.63b USD
EBITDA TTM = -1.60b USD
Long Term Debt = 487.4m USD (from longTermDebt, last quarter)
Short Term Debt = 16.8m USD (from shortTermDebt, last quarter)
Debt = 796.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 154.5m
Net Debt = -2.45b USD (calculated: Debt 796.4m - CCE 3.25b)
Enterprise Value = 42.1b USD (44.6b + Debt 796.4m - CCE 3.25b)
Interest Coverage Ratio = -27.42 (Ebit TTM -1.63b / Interest Expense TTM 59.3m)
EV/FCF = -22.40x (Enterprise Value 42.1b / FCF TTM -1.88b)
FCF Yield = -4.46% (FCF TTM -1.88b / Enterprise Value 42.1b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 16.6m) / Revenue TTM)
Tobins Q-Ratio = 9.74 (Enterprise Value 42.1b / Total Assets 4.32b)
Interest Expense / Debt = 7.45% (Interest Expense 59.3m / Debt 796.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.29b (EBIT -1.63b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.10 (Total Current Assets 4.03b / Total Current Liabilities 442.5m)
Debt / Equity = 0.31 (Debt 796.4m / totalStockholderEquity, last quarter 2.61b)
Debt / EBITDA = 1.53 (negative EBITDA) (Net Debt -2.45b / EBITDA -1.60b)
Debt / FCF = 1.30 (negative FCF - burning cash) (Net Debt -2.45b / FCF TTM -1.88b)
Total Stockholder Equity = 1.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -52.37% (Net Income -1.77b / Total Assets 4.32b)
RoE = -96.44% (Net Income TTM -1.77b / Total Stockholder Equity 1.83b)
RoCE = -70.11% (EBIT -1.63b / Capital Employed (Equity 1.83b + L.T.Debt 487.4m))
RoIC = -32.25% (negative operating profit) (NOPAT -1.29b / Invested Capital 3.99b)
WACC = 11.16% (E(44.6b)/V(45.4b) * Re(11.25%) + D(796.4m)/V(45.4b) * Rd(7.45%) * (1-Tc(0.21)))
Discount Rate = 11.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.03 | Cagr: 11.61%
[DCF] Fair Price = unknown (Cash Flow -1.88b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.03 | # QB: -5
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -1.65 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-2.45 | Chg30d=-23.29% | Revisions=-75% | Analysts=17
EPS current Year (2026-12-31): EPS=-9.76 | Chg30d=-21.03% | Revisions=-53% | GrowthEPS=-64.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-6.53 | Chg30d=-12.64% | Revisions=-31% | GrowthEPS=+33.1% | GrowthRev=+786.1%
[Analyst] Revisions Ratio: -62% (up=5, down=26)